Sitagliptin/ertugliflozin
A combination medication used in the management of type 2 diabetes mellitus.
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Sitagliptin/ertugliflozin is a combination medication used in the management of type 2 diabetes mellitus. It combines two active ingredients: sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor. This combination is designed to improve glycemic control in adults with type 2 diabetes when diet and exercise alone do not provide adequate control.
Pharmacology[edit | edit source]
Sitagliptin[edit | edit source]
Sitagliptin works by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the breakdown of incretin hormones, which are involved in the regulation of glucose homeostasis. By inhibiting DPP-4, sitagliptin increases the levels of active incretin hormones, leading to increased insulin release and decreased glucagon levels in the blood in a glucose-dependent manner.
Ertugliflozin[edit | edit source]
Ertugliflozin is an SGLT2 inhibitor that works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This mechanism helps to lower blood glucose levels in patients with type 2 diabetes.
Clinical Use[edit | edit source]
Sitagliptin/ertugliflozin is indicated for the treatment of type 2 diabetes mellitus in adults. It is typically used in conjunction with diet and exercise to improve glycemic control. The combination of these two agents provides a complementary mechanism of action, targeting both insulin secretion and glucose reabsorption.
Side Effects[edit | edit source]
Common side effects of sitagliptin/ertugliflozin include:
- Hypoglycemia, especially when used with insulin or sulfonylureas.
- Urinary tract infections
- Genital mycotic infections
- Increased urination
Serious side effects may include:
- Ketoacidosis
- Acute kidney injury
- Pancreatitis
Contraindications[edit | edit source]
Sitagliptin/ertugliflozin is contraindicated in patients with:
- Severe renal impairment
- End-stage renal disease
- Hypersensitivity to any of the components
Also see[edit | edit source]
- Type 2 diabetes mellitus
- Sitagliptin
- Ertugliflozin
- Dipeptidyl peptidase-4 inhibitors
- Sodium-glucose co-transporter-2 inhibitors
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
